logo
Plus   Neg
Share
Email

Adtran Q1 Profit Declines; Declares Cash Dividend - Quick Facts

Networking and communications equipment provider ADTRAN Inc. (ADTN) reported that its first quarter net income declined to $12.96 million from $34.26 million in the prior year quarter. Earnings per share, assuming dilution, were $0.20 for the quarter compared to $0.52 a year earlier. Non-GAAP earnings per share for the quarter were $0.25 compared to $0.55 for the first quarter of 2011.

On average, 11 analysts polled by Thomson Reuters expected earnings of $0.20 per share for the quarter. Analysts' estimates usually exclude one-time items

Quarterly sales were $134.74 million, down from $165.52 million in the previous year. Analysts expected the company to generate revenues of $134.15 million for the quarter.

The company also announced that its Board of Directors declared first quarter cash dividend of $0.09 per common share to be paid to holders of record at the close of business on April 26, 2012. The ex-dividend date is April 24, 2012 and the payment date is May 10, 2012.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT